Zylo Therapeutics, Inc.
Zylö Therapeutics is dedicated to enhancing drug delivery through innovative encapsulation technologies, specifically utilizing their proprietary Z-pods®. Their mission is to improve product performance across various market segments by increasing bioavailability, stability, and targeted delivery of therapeutic compounds.
Industries
Nr. of Employees
small (1-50)
Zylo Therapeutics, Inc.
105A Ben Hamby Rd., Greenville, SC 29615
Products
Amorphous silica particle delivery platform
A particle-based delivery platform composed of engineered amorphous silica particles designed to encapsulate diverse payloads to improve stability, solubility, bioavailability, and enable targeted or sustained local delivery (including sustained nitric-oxide release).
Amorphous silica particle delivery platform
A particle-based delivery platform composed of engineered amorphous silica particles designed to encapsulate diverse payloads to improve stability, solubility, bioavailability, and enable targeted or sustained local delivery (including sustained nitric-oxide release).
Services
Co-development of particle-encapsulated formulations for improved stability, solubility, bioavailability, or targeted topical delivery for pharma, OTC, cosmetic, and animal-health applications.
Design and execution of preclinical animal studies and associated activities intended to support IND-enabling packages and early clinical translation.
Scale-up of particle formulation manufacturing with implementation of ISO-9001-aligned quality management practices and cGMP-ready processes to support clinical supply.
Co-development of particle-encapsulated formulations for improved stability, solubility, bioavailability, or targeted topical delivery for pharma, OTC, cosmetic, and animal-health applications.
Design and execution of preclinical animal studies and associated activities intended to support IND-enabling packages and early clinical translation.
Scale-up of particle formulation manufacturing with implementation of ISO-9001-aligned quality management practices and cGMP-ready processes to support clinical supply.
Expertise Areas
- Nanoparticle-based drug delivery
- Topical and transdermal formulation development
- Nitric oxide-releasing therapeutic systems
- Solubility enhancement and formulation optimization
Key Technologies
- Amorphous silica nanoparticle/microparticle encapsulation
- Nitric oxide-releasing particle systems
- Sustained-release delivery technologies
- Topical/transdermal nanoparticle delivery
News & Updates
Finalist of InnoVision’s 2023 competition
Zylö Therapeutics was a finalist for top technology applications in South Carolina, with the winner to be announced in October 2023.
Winner of Pitch Contest at SCBIO’s Annual Conference
Zylö Therapeutics won the pitch contest at SCBIO’s Annual Conference in Charleston, SC in 2023.
Winner of InnoVision's 2022 award
Zylö Therapeutics was awarded the top technology company in South Carolina in 2022.
Awarded by the NIH for the development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus in 2023.
$260,000 Phase 1 SBIR grant
Awarded by the NIH for the optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction in 2022.
$600,000 Phase 1 SBIR grant
Awarded by the NIH for the development and optimization of a nitric oxide releasing microparticle-based topical treatment for onychomycosis in 2022.
Finalist of InnoVision’s 2023 competition
Zylö Therapeutics was a finalist for top technology applications in South Carolina, with the winner to be announced in October 2023.
Winner of Pitch Contest at SCBIO’s Annual Conference
Zylö Therapeutics won the pitch contest at SCBIO’s Annual Conference in Charleston, SC in 2023.
Winner of InnoVision's 2022 award
Zylö Therapeutics was awarded the top technology company in South Carolina in 2022.
Awarded by the NIH for the development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus in 2023.
$260,000 Phase 1 SBIR grant
Awarded by the NIH for the optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction in 2022.
$600,000 Phase 1 SBIR grant
Awarded by the NIH for the development and optimization of a nitric oxide releasing microparticle-based topical treatment for onychomycosis in 2022.